Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ERTUGLIFLOZIN PIDOLATE\SITAGLIPTIN: 89 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
89
Total FAERS Reports
3 (3.4%)
Deaths Reported
28
Hospitalizations
89
As Primary/Secondary Suspect
5
Life-Threatening
1
Disabilities

Active Ingredient: ERTUGLIFLOZIN PIDOLATE\SITAGLIPTIN PHOSPHATE ·

First Report: 20180611 · Latest Report: 20240713

What Are the Most Common ERTUGLIFLOZIN PIDOLATE\SITAGLIPTIN Side Effects?

#1 Most Reported
Vomiting
13 reports (14.6%)
#2 Most Reported
Gastrointestinal haemorrhage
12 reports (13.5%)
#3 Most Reported
Covid-19 pneumonia
12 reports (13.5%)

All ERTUGLIFLOZIN PIDOLATE\SITAGLIPTIN Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Vomiting 13 14.6% 0 13
Covid-19 12 13.5% 0 12
Covid-19 pneumonia 12 13.5% 0 12
Gastrointestinal haemorrhage 12 13.5% 0 12
Product dose omission issue 9 10.1% 0 0
Blood glucose increased 7 7.9% 0 1
No adverse event 6 6.7% 0 0
Ketoacidosis 5 5.6% 0 4
Rash 5 5.6% 0 0

Who Reports ERTUGLIFLOZIN PIDOLATE\SITAGLIPTIN Side Effects? Age & Gender Data

Gender: 35.2% female, 64.8% male. Average age: 59.4 years. Most reports from: US. View detailed demographics →

Is ERTUGLIFLOZIN PIDOLATE\SITAGLIPTIN Getting Safer? Reports by Year

YearReportsDeathsHosp.
2018 4 0 1
2019 14 2 5
2020 11 0 0
2021 6 0 1
2023 18 0 15
2024 1 0 0

View full timeline →

What Is ERTUGLIFLOZIN PIDOLATE\SITAGLIPTIN Used For?

IndicationReports
Type 2 diabetes mellitus 27
Diabetes mellitus 21
Product used for unknown indication 12

Official FDA Label for ERTUGLIFLOZIN PIDOLATE\SITAGLIPTIN

Official prescribing information from the FDA-approved drug label.